Camlin Fine Sciences
Stock Snapshot
Price Performance
Vista Outlook
View Technicals Analysis →Basis of our Recommendation
Camlin Fine Sciences is strategically transitioning from a commodity-focused antioxidant manufacturer to a diversified specialty ingredients provider, which is expected to enhance its revenue growth and margins. Management's commentary highlights the integration of the Vinpai acquisition as a key driver for expanding its portfolio into high-growth natural functional ingredients, thereby improving market reach and R&D capabilities. Despite facing temporary headwinds such as high raw material prices and logistics costs, management remains cautiously optimistic about achieving double-digit EBITDA margins by H2FY27, supported by operational leverage and cost rationalization efforts. Vista's financial outlook reflects stable revenue growth and margins, aligning with management's expectations, while the company's fair valuation suggests limited upside potential. The performance materials and additives industry is experiencing a sunrise phase, driven by infrastructure and automotive demand, which further supports Camlin's growth trajectory. However, key risks include geopolitical trade disruptions and competitive pricing pressures, particularly from Chinese manufacturers. Over the next 12-24 months, opportunities lie in the successful commercialization of new specialty ingredients and the continued growth of the Blends segment, while watchpoints include raw material volatility and the impact of ongoing geopolitical tensions
Why We Like This Stock
- Strategic acquisition of Vinpai enhances product diversification and market reach
- Management's focus on operational efficiency and cost rationalization supports margin improvement
- The performance materials industry is in a growth phase, driven by infrastructure and automotive demand
Things To Watch Out For
- High raw material prices and logistics costs pose ongoing challenges to profitability
- Geopolitical tensions may disrupt supply chains and impact growth
- Intense competitive pressures, particularly from Chinese manufacturers, could affect pricing power
Key Parameters
Financial Snapshot
| Actuals | Forecast | ||||
|---|---|---|---|---|---|
| FY24 | FY25 | FY26 | FY27 | FY28 | |
| Revenue (Cr.) | 1,454 | 1,667 | 1,723 | 2,000 | 2,176 |
| Profit Before Tax (Cr.) | 59 | 60 | -7 | 12 | 30 |
| PBT Margin | 4.1% | 3.6% | -38.4% | 0.6% | 1.4% |
| Net Profit (Cr.) | -124 | -192 | 9 | 9 | 14 |
| Earnings Per Share | -5.8 | -9.0 | 0.7 | 0.3 | 0.7 |
Analyst Recommendations
| Broker | Recommendation | Target Price | Date |
|---|---|---|---|
| Axis Securities | ▲ Buy | 165 | 12-Aug-2026 |
Company Overview
Show Company Profile
Camlin Fine Sciences Limited, together with its subsidiaries, research, develops, manufactures, and markets specialty chemicals, ingredients, and additive blend products in India and internationally. The company offers shelf-life solutions, which include basic ingredients, such as tert-butylhydroquinone (TBHQ), Butylated Hydroxyanisole (BHA), Butylated Hydroxytoluene (BHT), and Ascorbyl Palmitate (ASP); aroma ingredients, including vanillin and ethyl vanillin, natural vanillin, and some of its combinations; performance chemicals that include Hydroquinone (HQ), Catechol (CAT), Monomethyl Ether of HQ (MEHQ), tert butylcatechol (TBC), Guaiacol, and Veratrole; and health and wellness products comprising algae based products, such as Omega 3 fatty acids. It sells its prodycrts under the Xtendra, Nasure, Ezential, adorr, Dinamic, and Biosus brands. The company's products are used in food and beverage, pet food and rendering, animal nutrition, petrochemical, nutrition and health, biofuel, agrochemical, pharmaceutical, polymers, fragrance and flavor, and dyes and pigments industries. The company was formerly known as Camlin Fine Chemicals Ltd. and changed its name to Camlin Fine Sciences Limited in August 2011. Camlin Fine Sciences Limited was founded in 1931 and is headquartered in Mumbai, India.